About Zucara Therapeutics

Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type 1 diabetes is not properly controlled. It has demonstrated potential to specifically block somatostatin type 2 receptors in the pancreas thereby preventing hypoglycemia and restoring natural glucose levels in the blood. Zucara’s method offers a clea

Repeat Founder
Company Highlights
Year Founded

2015

icon-altEmployees

10

Location (HQ)

CAN

Since Last Funding

1 year 2 months

Monthly Website Visitors

6.7K

icon-altTotal Investment Amt

$29M

Last Funding Round

Grant

icon-altYoY Headcount Growth

-9.01%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Similar Companies

Pharmaceutical

Biotechnology

Biotechnology Research

Diabetes